Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving PremarketBenzinga • Thursday
Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key MetricsZacks Investment Research • Thursday
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing DealZacks Investment Research • 10/09/26
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract SurgeryBusiness Wire • 10/09/26
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing DealBenzinga • 10/08/26
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal DiseasesBusiness Wire • 10/08/26
Glaukos says late-stage eye disease treatment shows lasting benefits after single doseReuters • 10/07/26
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in KeratoconusBusiness Wire • 10/07/26
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28Business Wire • 10/07/26
Here's Why You Should Retain Glaukos Stock in Your Portfolio for NowZacks Investment Research • 09/24/26
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of KeratoconusBusiness Wire • 09/23/26
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 08/28/26